AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19

Recruitingn/aAges 18 Years - anyAllHellenic Institute for the Study of Sepsis
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). Thus, there is an essential need for a better knowledge, tools, clinical guidelines and recommendations that it will make it possible to reduce this overrepresentation of NCDs as a consequence of the post-acute phase (PAP) of COVID-19. The overall concept underpinning "POINT" is to i) build detailed knowledge on the link between the PAP of COVID-19 caused by previous,

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Group A (comparators) 1. Adults (18 years or more) of both genders 2. Negative history of acute COVID-19 Group B (patients with ฮฮŸ dysfunction) 1. Adults (18 years or more) of both genders 2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply 3. Absence of any current overt organ dysfunction 4. Absence of signs of any organ dysfunction during acute COVID-19 Group C (patients with dysfunctions) 1. Adults (18 years or more) of both genders 2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply 3. Presence of signs of organ dysfunction of the lung, the kidneys or the heart during acute COVID-19 Exclusion Criteria: Group A (comparators) 1. Any other co-existing disorder generating clinical symptoms 2. Failure to thrive according to the attending physicians 3. Pregnancy or lactation Group B (patients with ฮฮŸ dysfunction) 1. Any other co-existing disorder generating clinical symptoms 2. Failure to thrive according to the attending physicians 3. Pregnancy or lactation Group C (patients with dysfunctions) 1. Any other co-existing disorder generating clinical symptoms 2. Medical history of any of: * stage III or IV chronic obstructive pulmonary disease according to the GOLD criteria * pulmonary fibrosis or pulmonary hypertension * stage IV solid tumour malignancy under chemotherapy or radiotherapy * systemic sclerosis * congestive heart failure * stage II, III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19 3. Limited chance of survival for at least six months due to co-existing comorbidity(-ies) according to the judgement of the attending physicians 4. Pregnancy or lactation
๐Ÿ’Š

What it tests

  • Blood samples
  • Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
๐Ÿ“

Where

6 sites
10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases
Athens, Greece
4th Department of Internal Medicine, ATTIKON University General Hospital
Athens, Greece
Obstructive Diseases Clinic, Sotiria Athens Hospital of Chest Diseases
Athens, Greece
Out-patient department of Infectious Diseases, Sotiria Athens Hospital of Chest Diseases
Athens, Greece
1st Department of Internal Medicine, Thriasio General Hospital of Elefsina
Elefsina, Greece
2nd Department of Internal Medicine, Thriasio General Hospital of Elefsina
Elefsina, Greece
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy